BIOCURE TECHNOLOGY INC. (1WH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BIOCURE TECHNOLOGY INC. (1WH) has a cash flow conversion efficiency ratio of -0.005x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-8.28K ≈ $-9.68K USD) by net assets (€1.58 Million ≈ $1.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BIOCURE TECHNOLOGY INC. defensive interval ratio to measure how many days the company can operate on defensive assets alone.
BIOCURE TECHNOLOGY INC. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how BIOCURE TECHNOLOGY INC.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
BIOCURE TECHNOLOGY INC. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BIOCURE TECHNOLOGY INC. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rare Foods Australia Ltd
AU:RFA
|
-0.026x |
|
Severfield PLC
LSE:SFR
|
0.125x |
|
Venture Life Group PLC
LSE:VLG
|
-0.012x |
|
International Frontier Resources Corporation
V:IFR
|
0.017x |
|
Satis Group S.A.
WAR:STS
|
0.000x |
|
Protagenic Therapeutics
NASDAQ:PTIX
|
0.087x |
|
Intercede Group
LSE:IGP
|
0.071x |
|
Tearlach Resources Ltd
V:TEA
|
-0.043x |
Annual Cash Flow Conversion Efficiency for BIOCURE TECHNOLOGY INC. (2021–2025)
The table below shows the annual cash flow conversion efficiency of BIOCURE TECHNOLOGY INC. from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see BIOCURE TECHNOLOGY INC. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.58 Million ≈ $1.84 Million |
€-76.52K ≈ $-89.46K |
-0.049x | -574.70% |
| 2024-12-31 | €1.34 Million ≈ $1.57 Million |
€13.71K ≈ $16.03K |
0.010x | +107.55% |
| 2023-12-31 | €1.60 Million ≈ $1.87 Million |
€-217.13K ≈ $-253.84K |
-0.135x | -138.52% |
| 2022-12-31 | €-2.33 Million ≈ $-2.72 Million |
€-818.38K ≈ $-956.77K |
0.352x | -72.34% |
| 2021-12-31 | €-852.32K ≈ $-996.45K |
€-1.08 Million ≈ $-1.27 Million |
1.271x | -- |
About BIOCURE TECHNOLOGY INC.
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab for age-related vision loss; and Filgrastim for chemotherapy effects treatments. It also engages in the research and development of CAR T … Read more